Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
REPLICATION

The Minimal Replicator of Epstein-Barr VirusoriP

John L. Yates, Sarah M. Camiolo, Jacqueline M. Bashaw
John L. Yates
Department of Genetics, Roswell Park Cancer Institute, Buffalo, New York 14263
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah M. Camiolo
Department of Genetics, Roswell Park Cancer Institute, Buffalo, New York 14263
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacqueline M. Bashaw
Department of Genetics, Roswell Park Cancer Institute, Buffalo, New York 14263
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JVI.74.10.4512-4522.2000
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Structure of oriP and relevant restriction sites (above) and its DS component (expanded below). The DS is considered to extend from nucleotide 9019 at the left edge of the dyad symmetry to nucleotide 9137, at an HpaI site, based on previous studies (5, 34). EBNA-1 binding sites 1 to 4 are numbered according to the method of Rawlins et al. (33). The three copies of the nonamer repeat, labeled a, b, and c as described by Vogel et al. (41), are indicated by solid arrows to indicate their relative orientations. The positions of two thymines, in the upper strand of site 4 and the lower strand of site 1, that become reactive to permanganate when EBNA-1 binds are indicated by “MnO4.” The 65-bp hyphenated dyad symmetry is indicated by the dotted lines with divergent arrows.

  • Fig. 2.
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Dependence of oriP-specific plasmid replication on EBNA-1 in 143B cells during the first 48 h after transfection. Duplicate dishes of 143B cells were transfected with test plasmids, pHyg (vector, “−”), pHEBo (pHyg carryingoriP, “wt”), or pHEBo carrying different mutations inoriP, as indicated for samples 1 to 10. For samples 11 and 12, cells were transfected with p367, which is pHEBo carrying the EBNA-1 gene. Plasmids were harvested from cells 48 h after transfection. For Southern analysis, 40% of each sample was digested with BamHI plus DpnI (upper blot), and 10% was digested with BamHI alone (lower blot). The percentages of total plasmid (lower blot) that replicated (full-length,DpnI-resistant plasmid, upper blot) were calculated by comparison to the quantitative standards of each blot. To test for the completeness of DpnI cutting, 2 ng of pHEBo was combined with DNA extracted from mock-transfected cells and digested withDpnI plus BamHI (lane marked “Co.,” upper blot). The standards were linearized pHEBo: 125 and 32 pg for the upper gel and 500 and 125 pg for the lower gel.

  • Fig. 3.
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    The DS component of oriP is an EBNA-1-dependent replicator. Duplicate plates of 293 cells were transfected with the oriP test plasmids as indicated. Cells were also cotransfected with either p367, a derivative of pHEBo that produces EBNA-1 (lanes 10 to 17), or with p396, a similar plasmid that produces mutant EBNA-1 that cannot bind to DNA (lanes 2 to 9). Plasmids were extracted from cells 46 h after transfection and were analyzed for DpnI-resistant plasmids (40% of each sample, upper blot) and total plasmids (2% of each sample, lower blot). The blots were processed in parallel using the same labeled probe, and signals from beta-image analysis were compared directly to calculate the percentages of replicated DNA. Stimulation by EBNA-1 is the ratio of the average amount of replication of each test plasmid in the presence of EBNA-1 to that in the absence of EBNA-1. NA, not applicable. A control for DpnI digestion was included in lane 1, upper blot, as was done for Fig. 2. The lower part of the gel containing the products of DpnI digestion is not shown.

  • Fig. 4.
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Analysis of EBNA-1 binding to DS mutants lacking individual binding sites, as determined by EMSA. An end-labeled, 278-bp DNA including the DS was prepared by PCR from wild-type oriPor from mutants lacking individual EBNA-1 binding sites, as indicated. EBNA-1 NΔ407 (26) was mixed with each DNA, using a molar ratio of EBNA-1 dimers to DNA of either 4 (for lanes 1, 3, 6, 9, 12, and 15) or 16 (for lanes 4, 7, 10, 13, and 16). EBNA-1 was omitted from lanes 2, 5, 8, 11, and 14. Complexes were electrophoresed through a 4% polyacrylamide gel. At the left, the positions of free probe (F) and complexes with EBNA-1 bound to one site, two sites, three sites, or all four sites are indicated. Complexes with two sites bound have different mobilities, depending primarily on whether the sites are in helical phase (2 IP) or out of helical phase (2 OP) (see the text).

  • Fig. 5.
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Long-term maintenance of plasmids carrying mutations inoriP in Raji cells. Shown is a Southern analysis of plasmids extracted from 3 million cells of two or four individual hygromycin B-resistant Raji clones carrying pHEBo (WT) or its mutant derivatives, as indicated at the top. The positions of supercoiled (CCC), relaxed circular (RC), and linear (L) forms of pHEBo are indicated at the left. “Chr.” marks the position of residual, fragmented chromosomal DNA, visible on the stained gel. As standards, 200- and 50-pg amounts of pHEBo were loaded in lanes 1 and 22, corresponding to 9 and 2.3 molecules per cell. The numbers of supercoiled monomeric plasmids detected per cell are given as the average for the bands that are bracketed.

  • Fig. 6.
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Support of long-term plasmid maintenance in 143/98.2 cells by oriP with various mutations at the DS. (A) Duplicate plates of cells were transfected with pHEBo (WT) or its derivatives carrying the indicated mutations at the DS. One-tenth of the cells were selected for hygromycin B resistance and then split successively 1:4 and 1:3 before being expanded and harvested at 18 to 21 days after transfection, except that in the case of the Δ1 3-Bst mutant, cells were not split and required 29 days for expansion. Plasmids extracted from ∼7 million cells were analyzed by Southern blot. For each plasmid tested, the average number of plasmid molecules detected per cell is indicated. The supercoiled (CCC) and relaxed circular (RC) forms of the plasmids are indicated. Note that the vector portion of the plasmids tested in lanes 15, 16, 19, and 20 is slightly smaller than the vector portion of the others (Table 1). (B) To convert the relative amounts detected in panel A to copies per cell, the samples of lanes 1 and 20 in panel A were analyzed again on this blot, in lanes 3 and 4, and compared to known amounts of pHEBo in lanes 1 and 2.

  • Fig. 7.
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    Activities of oriP mutants with substitutions of the nonamer repeats. (A) Duplicate plates of 143/98.2 cells were transfected with pHEBo or its derivatives carrying the indicated mutations. Cultures were split 1:10 before selection for hygromycin resistance, split 1:6 and 1:10 after selection, and harvested 20 to 21 days (lanes 2 to 11) or 24 days (lanes 12 to 23) after transfection. Plasmids extracted from approximately 5 million cells were analyzed by Southern blot. In lane 1, 50 pg of pHEBoΔRV was loaded as a standard corresponding to 1.4 copies per cell. The average calculated numbers of plasmid copies per cell are indicated. (B) Similar experiment to that shown in panel A except that cultures were grown without hygromycin B beyond the 13th day following transfection and the cultures were harvested sooner. After selection, the resistant cultures were split successively 1:10 and then 1:2, except as noted below, and harvested at 15 to 16 days following transfection. With Δ3-4, c-Stu, the cultures could only be split once at 1:5 after selection and before harvesting. With Δ1-4, the cultures were not split after selection and could not be harvested until 24 days posttransfection. The relative average numbers of plasmids detected have been indicated, with pHEBo (WT) set arbitrarily at 10.

  • Fig. 8.
    • Open in new tab
    • Download powerpoint
    Fig. 8.

    Activity of oriP when the EBNA-1 binding sites at the DS were made to resemble FR consensus binding sites. (A) 143B/98.2 cells were transfected with plasmids carrying the indicated mutations, selected for hygromycin resistance, and propagated as described for Fig. 6. Cultures were harvested 20 to 21 days (lanes 1 to 8) or 25 to 26 days (lanes 9 to 20) after transfection. Average number of plasmid copies per cell are indicated. (B) The samples from lanes 1 and 19 were analyzed again on this blot (lanes 3 and 4) in comparison to known amounts of plasmid (lanes 1 and 2) to provide references for quantitating the signals of the blot in panel A.

Tables

  • Figures
  • Table 1.

    Plasmids carrying mutations at oriP

    PlasmidMutation(s)Description of mutation(s)
    p571aΔ1-4Deletion of EBNA-1 sites 1 to 4, positions 8995 to 9134 (EcoRV toHpaI)
    p568aΔ1Deletion of EBNA-1 site 1, positions 9107 to 9134 (SmaI toHpaI)
    p653a1-Bst9107-GGGAAGCAGTATACACCC (mutant EBNA-1 site 1, substitution underlined)
    p654a2-Bst9086-GGATGTATACTACTACTA (mutant EBNA-1 site 2)
    p655a3-Bst9053-GGGTAACAGTATACATTG (mutant EBNA-1 site 3)
    p656a4-Bst9032-CGATGTATACTGCTTCCC (mutant EBNA-1 site 4)
    p657aΔ1, 2-Bst
    p658aΔ1, 3-Bst
    p659aΔ9009–9066Positions 9009 to 9066 replaced by TAC
    p688b3-Bst, 4-Bst
    p689aΔ9036–9066Positions 9036 to 9066 replaced by GTATAC (Bst1107 I site)
    p727bΔ8994–9018Positions 8994 to 9018 replaced by GCTC (created SstI site)
    p715bS, X, Δ3-4S = TA to GC at positions 8994 8995 (made SstI site); X = G to A at position 9086 (made XbaI site); Δ3-4 = deletion of positions 8996 to 9082, including EBNA-1 sites 3 and 4
    p716bS, X, Δ3-4, 2con2con = position 9091 T to consensus C; position 9097 A to consensus G
    p717bS, X, Δ3-4, 1con1con = position 9110 A to consensus T
    p718bS, X, Δ3-4, 1con, 2con
    p738bS, X, 4con4con = position 9046 T to consensus A
    p739bS, X, 4con, 1con
    p740bS, X, 4con, Δ1-2Δ1-2 = deletion of EBNA-1 sites 1 and 2, positions 9088 to 9134 (XbaI to HpaI)
    p751b, cS, X
    p752b, cS, X, Δ1-2
    p753bS, X, a-Ttha-Tth = 9020-CTAACCCTAATT to AGACTTTGTCAA
    p754bS, X, a-Tth, Δ1
    p755bS, X, a-Tth, b-Tthb-Tth = 9071-AATTAGGGTTAG to AGACTTTGTCAA
    p756bS, X, a-Tth, b-Tth, Δ1
    p758bS, X, Δ1-2, a-Tth
    p766bS, X, Δ1-2, a-Tth, b-Tth
    p784bS, X, a-Tth, b-Tth, c-Stuc-Stu = 9127-TTAGGGTTA to ACTTCAGGA
    p785b, cS, X, c-Stu
    p785ΔX, Δ3-4′, c-StuΔ3-4′ = deletion of positions 8993 to 9082
    • ↵a Constructed in pHEBo (p152) (39).

    • ↵b Constructed in pHEBoΔRV and identical to pHEBo except deleted for 349 bp between ClaI andBamHI sites to remove an EcoRV site.

    • ↵c Also contains an inadvertent and apparently innocuous mutation, T to A at position 9079.

  • Table 2.

    Frequencies of establishment of hygromycin B-resistant clones of Raji cells after electroporation with plasmids carrying wild-type or mutant oriP

    Wild type or oriP mutantNo. of positive wells, of 16 tested at:Frequencya
    10,000 cells/well1,000 cells/well100 cells/well
    Wild type16, 1616, 1616, 16>3 × 10−2
    Δ1-40, 00, 00, 0<6 × 10−6
    Δ116, 1616, 152, 63 × 10−3
    1-Bst16, 1614, 152, 32 × 10−3
    2-Bst16, 1616, 163, 43 × 10−3
    3-Bst16, 1616, 166, 44 × 10−3
    4-Bst16, 1616, 168, 98 × 10−3
    Δ1 2-Bst16, 162, 70, 04 × 10−4
    Δ1 3-Bst0, 00, 00, 0<6 × 10−6
    Δ9009–90662, 30, 00, 02 × 10−5
    • ↵a Average number of G418-resistant clones per cell plated as estimated by fluctuation analysis.

PreviousNext
Back to top
Download PDF
Citation Tools
The Minimal Replicator of Epstein-Barr VirusoriP
John L. Yates, Sarah M. Camiolo, Jacqueline M. Bashaw
Journal of Virology May 2000, 74 (10) 4512-4522; DOI: 10.1128/JVI.74.10.4512-4522.2000

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Minimal Replicator of Epstein-Barr VirusoriP
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The Minimal Replicator of Epstein-Barr VirusoriP
John L. Yates, Sarah M. Camiolo, Jacqueline M. Bashaw
Journal of Virology May 2000, 74 (10) 4512-4522; DOI: 10.1128/JVI.74.10.4512-4522.2000
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514